HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Ancriviroc

CCR5 receptor antagonist

Also Known As:

4-((4-bromophenyl)-(ethoxyimino)methyl)-1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl-1,4'-bipiperidine N-oxide; SCH 351125; SCH-351125; SCH351125

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - Ancriviroc: 5
- Heterocyclic Oxides
  - Cyclic N-Oxides: 3
    - Ancriviroc: 5
Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Oximes: 1292
      - Ancriviroc: 5

Experts

1.	Baroudy, B M: 2 articles (10/2001 - 10/2001)
2.	Clader, J W: 2 articles (10/2001 - 10/2001)
3.	Cox, K: 2 articles (10/2001 - 10/2001)
4.	Endres, M: 2 articles (10/2001 - 10/2001)
5.	Greenlee, W J: 2 articles (10/2001 - 10/2001)
6.	Palani, A: 2 articles (10/2001 - 10/2001)
7.	Shapiro, S: 2 articles (10/2001 - 10/2001)
8.	Arreaza, M Gladys: 1 article (09/2007)
9.	Bos, Jan D: 1 article (09/2007)
10.	Kraan, Maarten: 1 article (09/2007)

Related Diseases

1.	HIV Infections (HIV Infection) 03/01/2002 - "Schering-Plough is developing Sch-351125 (Sch-C), the lead in a series of CCR5 inhibitors, for the potential treatment of HIV infection. " 10/11/2001 - "Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection."
2.	Infections 07/04/2002 - "We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine N-oxide 1 (SCH 351125) as an orally bioavailable human CCR5 antagonist for the treatment of HIV-1 infection. " 10/23/2001 - "SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 09/01/2007 - "A randomized placebo-controlled clinical trial in 32 psoriasis patients revealed no significant clinical effect and no changes at the immunohistochemical level comparing patients treated with placebo or a CCR5 inhibitor SCH351125. "

Related Drugs and Biologics

1.	Oxides
2.	Chemokine Receptors